Navigation Links
Summit Brings Major Non-Profits, Venture, Pharma and Academics Together
Date:8/26/2013

CAMBRIDGE, Mass., Aug. 26, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today that its ninth annual Leadership Summit will take place on Thursday, October 3, 2013 at the Westin Copley Place Hotel in Boston, MA. Hosted by the world's first non-profit biotech, this public event explores the latest trends in drug discovery, partnering and financing drug development and clinical trials in neurodegeneration, specifically ALS.

(Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO)

The Leadership Summit will begin with a series of presentations from renowned industry leaders, including: Aaron Gitler, Ph.D., associate professor of genetics, Stanford University School of Medicine, who will present high-throughput screens to define novel mechanisms of ALS; Steve Finkbeiner, M.D., Ph.D., associate director and senior investigator, Gladstone Institutes, and professor, UCSF, who will discuss using Nobel Prize-winning human induced pluripotent stem cell technology as drug discovery tools for ALS; Willem van Weperen, CEO, to-BBB, who will address novel approaches to overcoming the blood brain barrier when delivering drugs in ALS; and Steve Perrin, Ph.D., CEO and CSO, ALS TDI, who will provide a behind the scenes glimpse of the drug development pipeline at the world's largest ALS research institute, ALS TDI.

Additionally, the event will include a panel of prominent researchers and philanthropic experts involved in improving the pace at which new discoveries made in the lab are translated into health-improving treatments for patients today, including : Robert Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation; Mike Gold, M.D., VP clinical therapeutic area CNS, UCB Pharma; Amelie Gubitz, Ph.D., program director, extramural research program, NINDS; and Philip Reilly, M.D., J.D., venture partner at Third Rock Ventures. The panel will be moderated by Julie Donnelly, healthcare and life sciences reporter for the Boston Business Journal.

"To get a treatment to patients today takes more than just good science. It requires real partnerships between patients, pharma, biotech, academia, non-profits, for-profits, funders, investors, governments and others. Anyone with a stake in moving potential treatments forward for ALS and related neurodegenerative disorders should attend this important meeting," says Steve Perrin, Ph.D., CEO and CSO of ALS TDI.

The Institute will also announce this year's Leadership Award recipients during the Summit. Each year, ALS TDI recognizes active members within the ALS community who have been nominated by their peers for driving awareness of ALS and fundraising for research into effective treatments for the disease. This year's recipients include Andy Rubenstein of Cranbury, NJ; Jenny Dwyer of Kenmore, WA; Roger Petrone Jr. of Stamford, CT and Rick Cochran of Greenwich, CT; and Kevin Swan of Lakewood Ranch, FL. More information about the awards can be found online at www.als.net/summit/awards.

The ninth annual Leadership Summit begins at 9:00 a.m. and is free and open to the public. Lunch is provided, and there will be a cocktail and networking reception at the close. To learn more about the ALS TDI Leadership Summit and to register, please visit www.als.net/summit.  

About ALS
Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) is a progressive neurodegenerative disease that leads to paralysis, due to the death of motor neurons in the spinal cord and brain. There is no known cure for the disease. About 5,000 people in the US are diagnosed with ALS each year; the incidence is similar to multiple sclerosis. However, with no effective treatment, the average patient survives only two to five years following diagnosis. There are about 30,000 people in the US diagnosed with ALS today. The worldwide population of ALS patients is estimated at 450,000.

About ALS Therapy Development Institute (ALS TDI)
The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) as soon as possible for patients today. Focused on meeting this urgent unmet medical need, ALS TDI executes a robust target discovery program, while simultaneously operating the world's largest efforts to preclinically determine the efficacy of potential therapeutics, including a pipeline of dozens of small molecules, protein biologics, gene therapies and cell-based constructs. The world's first nonprofit biotech institute, ALS TDI employs 30 professional scientists, evaluates dozens of potential therapeutics each year and is currently executing a Phase IIA clinical trial of TDI-132 (Novartis' Gilenya®) in ALS patients.  Built by and for patients, the Cambridge, Massachusetts-based research institute collaborates with leaders in both academia and industry to accelerate ALS therapeutic development, including Biogen Idec, UCB, the Gladstone Institutes, MDA and RGK Foundation. For more information, please visit us online at www.als.net.

Media Contact:
Mari Sullivan, Public Relations Manager, ALS TDI, 617-441-7220, msullivan@als.net


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Fluke Biomedical to hold first Medical Device QA Training Summit
2. C to C Collaborations Foreseen at the Global Economic Summit 2013
3. GDS International Leads the Way for the Pharmaceutical Industry at its Upcoming NGP DD 30 Summit in Madrid
4. MRI Interventions CEO to Present at 2013 Brain Tumor Biotech Summit regarding MRI-Guided Therapies for Brain Cancer
5. BPSAs 3rd Annual Summit to Focus on Next Decade for Single-Use Biomanufacturing
6. 2013 Armada Specialty Pharmacy Summit Reports Record Attendance
7. Smart Water Leadership Summit Focused On Waterborne Disease Prevention in Healthcare Facilities To Be Held In Chicago June 6 & 7
8. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
9. Afya Foundation Donates Duffels Of Medical Supplies To African First Ladies At Summit In Los Angeles
10. CADCA Chairman And CEO To Discuss Costs Of Prescription Drug Abuse At National Rx Drug Abuse Summit
11. Plato BioPharma Presenting Preclinical capabilities at PKPD Summit Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):